Literature DB >> 15220681

Bacteriotherapy using fecal flora: toying with human motions.

Thomas J Borody1, Eloise F Warren, Sharyn M Leis, Rosa Surace, Ori Ashman, Steven Siarakas.   

Abstract

The intestinal flora may play a key role in the pathogenesis of certain gastrointestinal (GI) diseases. Components of bowel flora such as Lactobacillus acidophilus and Bifidobacterium bifidus have long been used empirically as therapeutic agents for GI disorders. More complex combinations of probiotics for therapeutic bacteriotherapy have also recently become available, however the most elaborate mix of human-derived probiotic bacteria is, by definition, the entire fecal flora. Fecal bacteriotherapy uses the complete normal human flora as a therapeutic probiotic mixture of living organisms. This type of bacteriotherapy has a longstanding history in animal health and has been used sporadically against chronic infections of the bowel, especially as a treatment of last resort for patients with severe Clostridium difficile syndromes including recurrent diarrhea, colitis, and pseudomembranous colitis. Encouraging results have also been observed following infusions of human fecal flora in patients with inflammatory bowel disease, irritable bowel syndrome, and chronic constipation. The therapeutic use of fecal bacteriotherapy is reviewed here and possible mechanisms of action and potential applications explored. Published reports on fecal bacteriotherapy are few in number, and detail the results of small uncontrolled open studies and case reports. Nevertheless, given the promising clinical responses, formal research into fecal bacteriotherapy is now warranted.

Entities:  

Mesh:

Year:  2004        PMID: 15220681     DOI: 10.1097/01.mcg.0000128988.13808.dc

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  92 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

3.  Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection.

Authors:  C A Duplessis; D You; M Johnson; A Speziale
Journal:  Infection       Date:  2011-12-08       Impact factor: 3.553

Review 4.  Human microbiome: From the bathroom to the bedside.

Authors:  Stephen Malnick; Ehud Melzer
Journal:  World J Gastrointest Pathophysiol       Date:  2015-08-15

5.  The Susceptibility of Celiac Disease Intestinal Microbiota to Clostridium difficile Infection.

Authors:  Masoumeh Azimirad; Mohammad Rostami-Nejad; Kamran Rostami; Tahere Naji; Mohammad Reza Zali
Journal:  Am J Gastroenterol       Date:  2015-12       Impact factor: 10.864

Review 6.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

Review 7.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10

8.  The correlation between Clostridium-difficile infection and human gut concentrations of Bacteroidetes phylum and clostridial species.

Authors:  E Goldberg; I Amir; M Zafran; U Gophna; Z Samra; S Pitlik; J Bishara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-19       Impact factor: 3.267

Review 9.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

10.  The Independent and Combined Effects of Omega-3 and Vitamin B12 in Ameliorating Propionic Acid Induced Biochemical Features in Juvenile Rats as Rodent Model of Autism.

Authors:  Hanan Alfawaz; Mona Al-Onazi; Sarah I Bukhari; Manal Binobead; Nashwa Othman; Norah Algahtani; Ramesa Shafi Bhat; Nadine M S Moubayed; Haya S Alzeer; Afaf El-Ansary
Journal:  J Mol Neurosci       Date:  2018-10-04       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.